Turenne Groupe
VC Fund
Paris, France
Turenne Groupe is a private equity firm focusing on healthcare, hotels, innovative industry, and ecotechnology industry.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Turenne Groupe invests in
Stages Turenne Groupe invests in
Countries Turenne Groupe invests in
Investment Focus
Industry
- Biotechnology 3 (60%)
- Medical 2 (40%)
- Health Care 2 (40%)
- Art 1 (20%)
- Internet 1 (20%)
Stage
- Series A 2 (40%)
- Series B 2 (40%)
- Venture - Series Unknown 1 (20%)
Country
- France 4 (80%)
- Switzerland 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
DeepLife uses deep learning on multi-omics data to model cells and efficiently engineer their behavior.DeepLife is a biotech company with a mission to build the next generation of system biology. The company works in a highly collaborative translational manner, to facilitate the transition of discoveries from the laboratory to patients. Thecompany operates through collaboration with academic groups in their respective areas of expertise. | $10M / Series A / Dec 11, 2024 | |
|
|
SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room. | $14M / Series B / Jul 16, 2024 | |
|
|
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M / Series A / Sep 18, 2023 | |
|
|
At Singulart, They are convinced that the digital space is an invaluable tool for bringing transparency and equity to the art market.They provide artists with the tools that enable them to independently manage the sale of their works. Their team is working around the clock, committing their energy to promoting Singulart artists to a globalaudience.In showcasing artists around the world, they also hope to allow art lovers and collectors alike to explore new artistic horizons, to embrace new cultures and to be inspired by the works of talented artists that they never would have come across if it wasn't for Singulart. | $67.7M / Series B / Nov 19, 2021 | |
|
|
NATUROPERA's vision is therefore to help change consumption to restore the balance of life. compositions and formulations respectful of the environment. | $4.6M / Venture - Series Unknown / Oct 06, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Turenne Groupe invest in?
Turenne Groupe invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Turenne Groupe last invest?
The most recent investment recorded for Turenne Groupe closed in Dec 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!